Zhejiang Haisen Pharmaceutical Co. Ltd. A

Haisen Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 65.7354 million yuan, up 8.13% from the same period last year. Total operating revenue was 251 million yuan, up 3.64% year-on-year, marking a third consecutive year of growth. Net cash inflow from operating activities was 75.4652 million yuan, up 1.53% year-on-year. The company's latest gross margin was 46.58%, up 2.05 percentage points year-on-year, achieving a fourth consecutive year of increase. The latest asset-liability ratio was 6.91%, down 1.38 percentage points year-on-year.

Haisen Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 65.7354 million yuan. The company's total operating revenue was 251 million yuan, and net cash inflow from operating activities was 75.4652 million yuan. The latest asset-liability ratio was 6.91 percent, up 0.38 percentage points from the previous quarter; gross margin was 46.58 percent, down 1.61 percentage points from the previous quarter; ROE was 4.25 percent, down 0.10 percentage points from the same period last year. Diluted earnings per share were 0.44 yuan, total asset turnover was 0.15 times, down 5.22 percent year on year, and inventory turnover was 1.24 times. The number of shareholders was 8,991, and the top ten shareholders held 118 million shares, accounting for 77.42 percent of total share capital.